Stocks · Cipla vs Zydus Lifesciences
Cipla vs Zydus Lifesciences: which mid-large pharma stock wins in 2026?
A global respiratory and chronic-therapy generics leader versus an India-first FMCG-pharma blend with a biosimilar optionality. A factual, signed comparison, informational and not a recommendation to buy or sell either stock.
The verdict
Cipla is the global generics company known for its respiratory franchise and a presence across the US, India and emerging markets, while Zydus Lifesciences is the India-anchored pharma-and-wellness company with a growing consumer-health business, a biosimilar pipeline and a strong domestic branded-generics portfolio. Both are established pharma names; the call is global-generics respiratory scale versus domestic-plus-biosimilar breadth. As of 2026-06-16, the systematic read scores Cipla Limited 72 and Zydus Lifesciences Limited 83 on the BazaarBaazi Crack Score, an Edge Score of 61 out of 100 to Zydus Lifesciences Limited.
BazaarBaaziSource & method
The matchup, at a glanceCIPLA 72 · ZYDUSLIFE 83
The Edge Score is a BazaarBaazi number for this matchup: 50 plus the gap between the two Crack Scores, capped at 100. 50 is a dead heat; the further above 50, the more decisively the systematic read favours the leader.
The case for eachStructural, not a tip
What each stock has going for it, factually. The Crack Score is the live systematic read; the edges are durable structural points, not forecasts.
The case for
Cipla Limited
Crack Score
72 / 100Mixed
Structural edges
- A differentiated respiratory franchise in inhaled generics, which carry higher barriers to entry than plain tablets.
- A broad India chronic-therapy brand portfolio that generates stable domestic cash flows.
- Emerging-market presence that diversifies the revenue base beyond the US.
The case for
Zydus Lifesciences Limited
Crack Score
83 / 100Bullish
Structural edges
- A consumer-wellness and OTC brand portfolio that adds a less-regulated, more premium revenue stream.
- Biosimilar development capability that gives long-run upside in regulated markets.
- A strong domestic branded-generics franchise with pricing power in chronic therapies.
The live ratios, side by sideQ4 FY26 results · live spot
Valuation and quality ratios computed from each company's latest filed results times its live spot, the same engine as the fundamentals calculator. The price-derived ratios (P/E, P/B, yield) move with the market; the rest hold until the next results.
| Cipla Limited | Zydus Lifesciences Limited | |
|---|---|---|
| Return on equity | 11.3% | n/a |
| Net profit margin | 13.9% | n/a |
| EPS growth (YoY) | -26.6% | n/a |
| Debt to equity | 0.02 | n/a |
Stored from each company's filed results, as of 2026-06-16 and currency-checked; anything we could not verify is shown as n/a rather than guessed. Move the price and watch them react in the calculator.
The comparison, side by sideFactual
Sector, indicative market cap, the live Crack Score and stance, then the structural read on each business. The live valuation and quality ratios are in the table above; read any ratio against the sector and the company's own history.
| Cipla Limited | Zydus Lifesciences Limited | |
|---|---|---|
| Sector | Pharmaceuticals | Pharmaceuticals |
| Market capIndicative band, refreshed monthly. Read the live figure from the latest screen. | ~1.1 lakh cr | ~1.1 lakh cr |
| Crack Score | 72 / 100 | 83 / 100 |
| Systematic stance | Mixed | Bullish |
| What they do | A large Indian pharma company with a focus on respiratory and chronic-therapy generics, sold across India, the US and emerging markets. | An Ahmedabad-based pharma and consumer wellness company with branded generics in India, a growing US generics book and a biosimilar pipeline. |
| The moat | Respiratory generics expertise, a large US inhalation pipeline and a strong chronic-therapy branded portfolio in India. | A branded-generics franchise in India with pricing power in chronic therapies, a consumer-wellness arm and biosimilar development capability. |
| Key driver 2026 to 2030 | US respiratory approvals (inhaled products), India chronic-therapy volume and emerging-market expansion. | India branded-generics growth, biosimilar launches in regulated markets and the consumer-wellness business scale. |
| Main risk | US generic price erosion, regulatory inspections and the pace of its inhalation-product approval cycle. | Regulatory timelines on biosimilars, competitive pressure in US generics and the pace of consumer-wellness margin improvement. |
| Best suited to | The investor who wants a global generics company with a differentiated respiratory pipeline. | The investor who wants India-branded-generics stability with biosimilar and consumer-wellness optionality. |
Compute the live valuation and quality ratios for either stock, or read the full signed verdict on CIPLA and ZYDUSLIFE.
FAQ4 reader questions · AEO-eligible
The Cipla vs Zydus Lifesciences call, distilled and schema-marked for AI Overview, Perplexity, and reader search.
Is Cipla or Zydus Lifesciences a better stock to buy?
Cipla is the global respiratory generics leader with a differentiated US pipeline, while Zydus is the India-first branded generics company with consumer wellness and biosimilar optionality. Pick global respiratory scale versus domestic-plus-biosimilar breadth, and use the fundamentals calculator to read each company's current P/E and return on equity from the latest results before deciding.
What makes Cipla's respiratory franchise valuable?
Inhalation generics like MDIs and DPIs require complex manufacturing and device expertise, which makes them harder to copy than plain tablet generics and therefore less subject to the same price erosion. Cipla has built an inhaled-generics capability over years, and its US pipeline includes products like generic Advair and Spiriva that carry significant market opportunity.
What is Zydus's biosimilar strategy?
Zydus has been developing biosimilar versions of biologic drugs whose patents are expiring in the US and Europe. Biosimilars require regulatory filings in the US under the 351(k) pathway, and approval timelines are longer than for small-molecule generics. A successful biosimilar launch can generate significant early-mover revenue before competition enters.
How does the India branded-generics business work?
In India, branded generics are drugs sold under brand names by the pharma company rather than the innovator. Doctors prescribe the brand, which gives the company pricing power similar to a branded product but with a generic molecule. Both Cipla and Zydus have large branded-generics franchises in India across chronic therapies like cardiovascular, anti-diabetic and respiratory.
Other matchups
Hub
Compare stocks
All stock head-to-heads
Compare
TCS vs Infosys
Margin and scale versus the guidance-led growth read
Compare
HDFC Bank vs ICICI Bank
Post-merger liability franchise versus best-in-class return discipline
Compare
SBI vs HDFC Bank
Sovereign-backed scale and value versus private-sector return quality
Compare
Reliance vs Bharti Airtel
Diversified conglomerate optionality versus a focused premium-telecom compounder
Compare
HAL vs BEL
Platform-maker order book versus faster-converting defence electronics
Compare
Maruti vs Tata Motors
Mass-market distribution and margins versus JLR-led global cyclicality
Compare
ONGC vs Coal India
Oil-price-linked upstream versus a coal monopoly with a dividend floor
Compare
ICICI Bank vs PNB
Best-in-class private return profile versus a PSU asset-quality recovery
Compare
Sun Pharma vs Cipla
Specialty-led US scale versus a balanced India and respiratory franchise
Compare
Trent vs Titan
Fast-fashion retail expansion versus a jewellery-led consumer compounder
Compare
Bajaj Finance vs Bajaj Finserv
The pure-play lending compounder versus the diversified financial-services holding
Compare
Adani Enterprises vs Adani Ports
The incubator conglomerate versus the cash-generating ports infrastructure operator
Compare
Tata Steel vs JSW Steel
An integrated global steelmaker versus a domestic-led capacity grower
Compare
NTPC vs Power Grid
Generation capacity growth versus regulated transmission stability
Compare
SBI vs ICICI Bank
Sovereign-backed scale and value versus best-in-class private return discipline
Compare
HUL vs Nestle India
Broad home and personal-care breadth versus a focused packaged-foods franchise
Compare
HDFC Bank vs Kotak Bank
Post-merger liability scale versus a focused, capital-efficient compounder
Compare
Axis Bank vs ICICI Bank
A large-franchise turnaround versus best-in-class return and earnings quality
Compare
TCS vs Wipro
Margin and scale leadership versus a leaner, restructuring-led recovery
Compare
Infosys vs HCLTech
Guidance-led pure-services read versus a differentiated products-and-engineering mix
Compare
Sun Pharma vs Dr Reddy's
Specialty-led US scale versus a generics-and-CDMO-led global diversification
Compare
Nestle India vs Britannia
Focused multi-category brand power versus a biscuits-led margin compounder
Compare
ITC vs HUL
Conglomerate cash-and-value versus the broadest mass-market FMCG compounder
Compare
UltraTech Cement vs Grasim
The cement industry leader versus an Aditya Birla conglomerate with a cement holding and new businesses
Compare
SBI Life vs HDFC Life
Bancassurance scale through SBI versus a diversified product mix and balanced distribution
Compare
L&T vs Siemens India
A diversified domestic engineering conglomerate versus a focused industrial-technology franchise
Compare
Bajaj Auto vs Eicher Motors
Export-led volume scale and EV push versus the premium Royal Enfield franchise
Compare
DMart vs Trent
Everyday-value grocery scale versus a fast-fashion and format-expansion story
Compare
Asian Paints vs Pidilite
Decorative paint leadership versus a monopoly in construction adhesives
Compare
DLF vs Lodha
The oldest premium residential-and-commercial franchise versus the fastest-growing pan-India developer
Compare
Tata Power vs Adani Green
A diversified integrated power company versus a pure-play utility-scale renewables developer
Compare
TVS Motor vs Hero MotoCorp
A premium-and-premium-EV challenger versus the mass-market volume king
Compare
Shree Cement vs Ambuja Cements
The highest-margin, most efficient pure-play cement operator versus Adani-backed capacity scale
Compare
Tech Mahindra vs LTIMindtree
A telecom-anchored restructuring story versus a high-quality engineering-and-digital merger compounder
Compare
Tata Consumer vs Varun Beverages
A multi-category Tata group FMCG build-out versus the fastest-growing PepsiCo bottler franchise in the world
Compare
Adani Power vs NTPC
A private-sector capacity-growth story versus the sovereign-backed power PSU with a renewable pivot
Compare
Cholamandalam vs Shriram Finance
A diversifying vehicle and home-finance NBFC versus the dominant used-commercial-vehicle lender
Compare
Hindalco vs Vedanta
A globally integrated aluminium-and-copper compounder versus a diversified natural-resources conglomerate
Compare
Mahindra vs Hyundai India
The SUV-led domestic compounder with a farm and EV platform versus the premium Korean franchise in the Indian market
Compare
PFC vs REC Ltd
Broader power financing platform versus a focused utility lender
Compare
Bank of Baroda vs Canara Bank
Diversified PSU franchise with international presence versus a sharper domestic recovery
Compare
Wipro vs HCLTech
Turnaround execution potential versus a steadier IT services and products blend
Compare
Godrej Consumer Products vs Dabur
Personal care and home care momentum versus defensive staples and wellness breadth
Compare
IndusInd Bank vs Kotak Bank
Higher-beta recovery potential versus quality-first private banking franchise
Compare
BPCL vs GAIL India
Downstream petroleum and refining leverage versus gas transmission and utility infrastructure
Compare
Tata Steel vs JSPL
Integrated steel scale and global diversification versus a focused domestic metals execution story
Compare
Torrent Pharma vs Divi's Labs
Branded formulations franchise versus specialty API and custom manufacturing excellence
Compare
ABB India vs CG Power
Premium electrification and automation technology versus a capital goods recovery and execution story
Compare
Motherson vs Bosch India
Global multi-category auto-component scale versus premium engineering and technology in auto systems
Compare
Muthoot Finance vs Bajaj Finance
Specialist gold-backed lending versus a broad consumer and retail credit platform
Compare
Adani Energy Solutions vs Tata Power
Transmission and distribution network expansion versus an integrated utility and clean energy franchise